ASCO 2026: FDA-Cleared AI Put to the Test - Top-Institutions - MDSpire

ASCO 2026: FDA-Cleared AI Put to the Test

Multimodal AI platform goes head-to-head with a standard breast cancer assay using routine pathology image

  • June 3, 2026

  • 3 min

Share

Top Institutions in Pathology

Brief introduction explaining scope and methodology.

  • #1

    University of Alabama at Birmingham
    University of Alabama at Birmingham

    Birmingham, AL

    Key Differentiators

    • Oncology

Original Source(s)

ASCO 2026: FDA-Cleared AI Put to the Test

  • June 3, 2026

Related Content

Predicting the prognosis of breast cancer patients by using nutrition-based index: a systematic review and meta-analysis

Distribution and molecular drivers of the 21-gene recurrence score in early breast cancer with low, intermediate, and high estrogen receptor expression

Correction: SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer